Wavefront-guided LASIK: a safe treatment for myopia & astigmatism

Article

Wavefront-guided LASIK is a safe and efficacious way to correct moderate to high myopia and compound myopic astigmatism.

Wavefront-guided LASIK is a safe and efficacious way to correct moderate to high myopia and compound myopic astigmatism, according to a study published in the January issue of the Journal of Cataract and Refractive Surgery.

Simon R. Bababeygya and co-workers from Stanford University School of Medicine, Stanford, California, USA conducted a retrospective study which included 89 eyes of 45 patients with moderate (-6.0 to -8.0 D) and high (>-8.00 D) myopia treated with wavefront-guided LASIK using the WaveScan linked to the CustomVue system (AMO). All eyes were analyzed preoperatively and one, three, and 12 months postoperatively.

Mean age was 38.4 years ±7.14 (SD) and no eye was retreated during the study. The mean manifest refraction spherical equivalent was -8.10±0.98 D (range -6.00 to -10.63 D) preoperatively and -0.33±0.55 D (range -1.625 to 1.375 D) 12 months postoperatively. Ninety percent of the eyes were within ±1.00 D of the intended correction and 64% were within ±0.50 D. For all eyes, the safety index was 1.00 and the efficacy index, 1.18.

The results of the study confirm that the correction of moderate to high myopia and compound myopic astigmatism using wavefront-guided LASIK is both safe and effective.

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.